Tristetraprolin (TTP) Protein Targets Inflammatory RNA For Rapid Destruction And When Researchers Boosted It In Elderly Mice, They Got Better Grip Strength, Healthier Bones And A More Youthful Immune Profile
According to ScienceDaily and the University at Buffalo, researchers have identified a protein called tristetraprolin, or TTP, that appears to put the brakes on the chronic inflammation linked to aging.
Older mice with boosted levels of the protein were stronger, more energetic and had healthier bones than untreated mice. The study was led by Keith Kirkwood, DDS, PhD, senior associate dean for research and Centennial Endowed Chair in the Department of Oral Biology at the University at Buffalo School of Dental Medicine, and published in the January 2026 issue of Aging and Disease.
To understand why this finding matters, it helps to understand what inflammaging actually is. Aging is not simply a process of wear. It is accompanied by a constant, low-level state of inflammation that builds across decades, gradually damaging tissues, weakening immunity, reducing muscle function, degrading bone density and undermining the body’s capacity for self-repair.
Scientists refer to this process as inflammaging, and Kirkwood describes it specifically: “These age-related changes, known as immunosenescence, lead to a decline in immune resilience and an increased susceptibility to age-related chronic inflammatory diseases.”
What makes inflammaging particularly difficult to address is its diffuse nature. It is not a single disease with a single cause. It is a systemic drift toward chronic activation of inflammatory pathways that, taken individually, are essential for survival.
The immune system is supposed to generate inflammation when responding to infection or injury. The problem in aging is that this response becomes dysregulated; perpetually activated at a low level even when no threat is present, consuming cellular resources, accelerating tissue damage and driving the physical deterioration that defines frailty.
TTP protein sits precisely at this mechanism. TTP is an RNA-binding protein that helps control inflammation by breaking down inflammatory signals before they can build up.
As people age, TTP protein levels naturally decrease, especially in immune cells. That drop may allow inflammation to become more widespread throughout the body. The elegance of TTP as a therapeutic target is that it does not suppress the immune system globally; it accelerates the degradation of specific pro-inflammatory messenger RNA molecules that would otherwise instruct cells to produce inflammatory mediators.
As Kirkwood explains: “This protein really targets RNA for rapid degradation. Most pro-inflammatory mediators have a very short half-life, meaning they only last for minutes, not hours.”
The research centred on mice that were 22 months old; considered elderly for mice. The team genetically modified a group of these elderly mice so that TTP remained stable rather than declining. Researchers then evaluated them using grip strength, walking speed, treadmill endurance and overall energy levels.
Male mice with increased TTP protein levels showed significantly lower frailty scores than untreated mice. Female mice also showed improvements, although the changes were smaller.
Kirkwood described the results directly: “The increase in TTP protein resulted in better grip strength, better walking, endurance and overall physical performance. These mice had healthier bones and reduced bone breakdown. They exhibited a more youthful-looking immune profile.”
The bone improvement across both sexes is particularly significant. Bone loss is one of the most clinically consequential aspects of aging, driving fracture risk, limiting mobility and contributing directly to the kind of falls that represent one of the leading causes of death in the elderly population.
A protein that reduces bone breakdown as part of a broader anti-inflammatory mechanism is not a minor finding. It points toward the possibility that inflammaging and osteoporosis share a deeper molecular driver than current treatments address.
The sex difference in outcome is also scientifically important. Female mice with higher TTP protein levels did not respond as strongly as males. Kirkwood says this may be related to their smaller body size and declining estrogen levels, which could limit how tissues respond to anti-inflammatory changes.
Even so, both male and female mice developed stronger bones when TTP expression was enhanced. This finding underscores a consistent pattern in aging research: biological sex is not a secondary variable. The molecular pathways that drive frailty differ between males and females in ways that will likely require sex-specific therapeutic strategies, not a single universal intervention.
The project was supported by a $2.1 million grant from the National Institutes of Health and carried out over six years at UB’s South and Downtown campuses. Kirkwood worked with longtime collaborators Bruce Troen, MD, professor and chief of geriatric medicine at the University of Kansas, and Perry Blackshear, MD, PhD, formerly of Duke University Medical Center and the National Institute of Environmental Health Science.
The scale of the problem this research is addressing cannot be overstated. By 2050, nearly one in four Americans will be age 65 or older, and many are expected to live well into their 90s. The prevalence of frailty in the non-nursing home population aged 65 and older is already approximately 15 percent. Modern medicine has extended lifespan successfully.
What it has not done is extend healthspan; the period of life during which a person remains physically capable and independent at the same rate. The result is a growing population of very old people living with significant physical limitation. TTP is not a cure for aging, but it is a molecular handle on one of aging’s most damaging processes.
Human treatments remain far away. Blackshear has already conducted early drug screening efforts to identify compounds capable of increasing TTP expression, but none have yet produced clear success. The team is now planning additional studies focused on whether TTP could also help reduce neuroinflammation linked to aging disorders such as dementia and Alzheimer’s disease.
That next step is arguably the most consequential frontier. Neuroinflammation is increasingly understood to be a central driver of Alzheimer’s disease rather than a secondary consequence of it. If TTP can reduce neuroinflammation in the brain with the same efficacy it demonstrates in muscles and bone, the implications extend from orthopedics and geriatric medicine into neurology; one of the least tractable domains in all of clinical research.
Kirkwood concluded: “I’m optimistic about where this research could lead and what we may learn as studies continue over time.”
One protein. Six years of study. Elderly mice that could grip harder, walk faster and hold stronger bones. If the translation to human biology follows, the clinical dividend could be a generation of older adults who remain independent, mobile and cognitively intact for longer than any previous generation. That is worth the next six years of work.
To check out our previous coverage on health science and medical research, read our articles here.
